(PDF) Molecular genetics of hemophilia A: Clinical perspectives
(PDF) CLINICOHEMATOLOGICAL STUDY OF HEMOPHILIA PATIENTS IN BHOPAL
(PDF) Postpartum Acquired Hemophilia A: Case Report and Literature Review
(PDF) Impact of novel hemophilia therapies around the world
(PDF) Clinical and Laboratory Approaches to Hemophilia A
VIDEO
Case of Hemophilia-A under recovery (PC
HEMATOLOGY MEDICINE lecture 13 HEMOPHILIA A in easy way
Highlights from ASH with Dr. Akshat Jain
What Do You Know About Hemophilia
The importance of thrombosis and hemostasis in hematology & hot topics in hemophilia research
How to Write a Scientific Research Paper
COMMENTS
Recent Advances in the Treatment of Hemophilia: A Review
The Replacement Therapy and Its Adverse Events. After assessing that hemophilia was due to the lack of a plasma clotting factor, 9 the disease's first treatment was introduced in 1948 by the infusion of plasma from healthy blood donors. 10 In 1958, Nilsson 1M and Blomback B in Sweden successfully treated HA patients with a globulin fraction of human plasma purified by the Cohn's ...
Hemophilia
Hemophilia, which means love (philia) of blood (hemo), is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and is characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. There is hemophilia C as well, which occurs due to deficiency ...
(PDF) Haemophilia
PDF | Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or deficiency of clotting factor VIII (FVIII) or IX (FIX),... | Find, read and cite all the research you ...
Past, present and future of hemophilia: a narrative review
Introduction. Hemophilia A and B are X chromosome-linked bleeding disorders included among the rare diseases and caused by mutations in the factor VIII (FVIII) and factor IX (FIX) genes [].Both factors take part in the intrinsic pathway of blood coagulation and affected individuals have severe, moderate and mild forms of the diseases, defined by factor plasma levels of 1% or less, 2 to 5% and ...
PDF The past and future of haemophilia: diagnosis, treatments, and its
Moderate haemophilia is defi ned as factor levels of 1-5 IU/dL (ie, 1-5% of normal), and mild disease as 5-40 IU/dL (ie, 5-40% of normal).4 Around 70% of patients have a positive family history of haemophilia. Haemophilia A can be diagnosed at an early age, sometimes even by measuring activity of factor VIII in the cord blood directly ...
Recent Advances in the Treatment of Hemophilia: A Review
Abstract. Progress in hemophilia therapy has been remarkable in the first 20 years of the third millennium, but the innovation began with the description the fractionation of plasma in 1946. The first concentrates followed the discovery of FVIII in the cryoprecipitate of frozen plasma and FIX in the supernatant in the early 1960s, which led to ...
Effects of replacement therapies with clotting factors in ...
The factor replacement therapies for hemophilia A were categorized according to the weekly doses used, based in the World Federation of Hemophilia Guidelines 2020 [6] as fol-lowing: low-dose (20 to <45 IU/kg per week), intermediate-dose (45 to <75 IU/kg per week), high-dose ( 75 IU/kg per week), and pharmacokinetic [PK]-prophylaxis (which ...
Treatment of Hemophilia
With a prevalence of 17.1 cases per 100,000 males, hemophilia A is the most frequent inherited disorder of blood coagulation.1 After the adoption of prophylactic replacement therapy with factor VII...
PDF A Study of Prospective Surveillance for Inhibitors among Persons with
Short title: Hemophilia Inhibitor Research Study Word Count: 3,113 Key Words: Surveillance, Haemophilia, Haemophilia inhibitor Corresponding author: J. Michael Soucie, PhD Centers for Disease Control and Prevention 1600 Clifton Road, MS E64, Atlanta, GA 30333 Phone 404-498-6737; Fax 404-498-9799 [email protected]
PDF Haemophilia A: A Review of Clinical Manifestations, Treatment
For this documentary research, publications were reviewed that considered knowledge about haemophilia A, its response to treatment, immunogenicity, bleeding episodes, quality of life, pharmacokinetics, treatment, and the development of inhibitors. The search was performed according to the following terms: haemophilia A, coagula-
(PDF) Haemophilia A: A Review of Clinical Manifestations, Treatment
Life Sciences and Health Research Group, Graduates School, CES University, Medellin 050021, C olombia 3 Hospital Universitario San Jorge, Pereira 660002, Colombia
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an AAV5-based gene-therapy vector that expresses a B-domain-deleted human factor VIII coding sequence from a hepatocyte-selective promoter. 8-10 ...
PDF Gene Therapy for Hemophilia B and An Update on Gene Therapy for ...
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply ... National Hemophilia Foundation, Medical and Scientific Advisory Council (MASAC) Recommendations, MASAC Document 272 - MASAC ...
The past and future of haemophilia: diagnosis, treatments, and its
Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic ...
Impact of novel hemophilia therapies around the world
Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approach in hemophilia. Since the 1950s, when prophylaxis started, factor concentrates have been improved with virus inactivation and molecule modification to ...
Haemophilia
This paper is a must-read for those who want to learn the story of gene therapy in haemophilia. PubMed Google Scholar Nathwani, A. C. Gene therapy for hemophilia.
Methodological quality and recommendations of hemophilia clinical
1. INTRODUCTION. Hemophilia is an inherited bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or IX (hemophilia B), both X‐linked recessive disorders. 1 Clinical manifestations relate to bleeding, bleeding sequelae, or complications of coagulation factor infusion. 2 It affects more than 1.2 million individuals worldwide, almost exclusively males. 3 Hemophilia ...
Haemophilia
About the Journal. Haemophilia is an international haematology journal dedicated to the worldwide exchange of information regarding the comprehensive care of haemophilia and blood disease. We are the official journal of both the World Federation of Hemophilia and the European Association for Haemophilia and Allied Disorders.
(PDF) Hemophilia and Its Treatment: Brief Review
emophilia derived from the Greek haima (Blood) and philia (Love), is a genetic bleeding disorder. caused by the def iciency of c lotting factor-VIII. (Hemophilia-A) or factor-IX (Hemophilia-B) or ...
Advances in the management of haemophilia: emerging treatments and
Mainstay haemophilia treatment, namely intravenous factor replacement, poses several clinical challenges including frequent injections due to the short half-life of recombinant factors, intravenous administration (which is particularly challenging in those with difficult venous access), and the risk of inhibitor development. These impact negatively upon quality of life and treatment compliance ...
Hematology Reports
The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact ...
PDF How to Write and Publish a Research Paper in Haemophilia
In order for a paper to be accepted for publication in a scientific journal, it must address a good research question, report the results of a well-designed study, and be written clearly. A good research question is clinically important, novel and timely—the right question at the right time. There are some helpful websites. The
Total Knee Arthroplasty in People with Hemophilia: Higher Incidence of
The purpose of this narrative review of the recent literature is to analyze the outcomes, complications, and implant survival of total knee arthroplasty (TKA) carried out on people with hemophilia (PWH). It has been shown that TKA substantially alleviates preoperative pain and improves knee function and the patient's quality of life. However, the complication rates of TKA range between 8.5% ...
Impact of novel hemophilia therapies around the world
Abstract. Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approach in hemophilia. Since the 1950s, when prophylaxis started, factor concentrates have been ...
IMAGES
VIDEO
COMMENTS
The Replacement Therapy and Its Adverse Events. After assessing that hemophilia was due to the lack of a plasma clotting factor, 9 the disease's first treatment was introduced in 1948 by the infusion of plasma from healthy blood donors. 10 In 1958, Nilsson 1M and Blomback B in Sweden successfully treated HA patients with a globulin fraction of human plasma purified by the Cohn's ...
Hemophilia, which means love (philia) of blood (hemo), is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and is characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. There is hemophilia C as well, which occurs due to deficiency ...
PDF | Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or deficiency of clotting factor VIII (FVIII) or IX (FIX),... | Find, read and cite all the research you ...
Introduction. Hemophilia A and B are X chromosome-linked bleeding disorders included among the rare diseases and caused by mutations in the factor VIII (FVIII) and factor IX (FIX) genes [].Both factors take part in the intrinsic pathway of blood coagulation and affected individuals have severe, moderate and mild forms of the diseases, defined by factor plasma levels of 1% or less, 2 to 5% and ...
Moderate haemophilia is defi ned as factor levels of 1-5 IU/dL (ie, 1-5% of normal), and mild disease as 5-40 IU/dL (ie, 5-40% of normal).4 Around 70% of patients have a positive family history of haemophilia. Haemophilia A can be diagnosed at an early age, sometimes even by measuring activity of factor VIII in the cord blood directly ...
Abstract. Progress in hemophilia therapy has been remarkable in the first 20 years of the third millennium, but the innovation began with the description the fractionation of plasma in 1946. The first concentrates followed the discovery of FVIII in the cryoprecipitate of frozen plasma and FIX in the supernatant in the early 1960s, which led to ...
The factor replacement therapies for hemophilia A were categorized according to the weekly doses used, based in the World Federation of Hemophilia Guidelines 2020 [6] as fol-lowing: low-dose (20 to <45 IU/kg per week), intermediate-dose (45 to <75 IU/kg per week), high-dose ( 75 IU/kg per week), and pharmacokinetic [PK]-prophylaxis (which ...
With a prevalence of 17.1 cases per 100,000 males, hemophilia A is the most frequent inherited disorder of blood coagulation.1 After the adoption of prophylactic replacement therapy with factor VII...
Short title: Hemophilia Inhibitor Research Study Word Count: 3,113 Key Words: Surveillance, Haemophilia, Haemophilia inhibitor Corresponding author: J. Michael Soucie, PhD Centers for Disease Control and Prevention 1600 Clifton Road, MS E64, Atlanta, GA 30333 Phone 404-498-6737; Fax 404-498-9799 [email protected]
For this documentary research, publications were reviewed that considered knowledge about haemophilia A, its response to treatment, immunogenicity, bleeding episodes, quality of life, pharmacokinetics, treatment, and the development of inhibitors. The search was performed according to the following terms: haemophilia A, coagula-
Life Sciences and Health Research Group, Graduates School, CES University, Medellin 050021, C olombia 3 Hospital Universitario San Jorge, Pereira 660002, Colombia
Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an AAV5-based gene-therapy vector that expresses a B-domain-deleted human factor VIII coding sequence from a hepatocyte-selective promoter. 8-10 ...
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply ... National Hemophilia Foundation, Medical and Scientific Advisory Council (MASAC) Recommendations, MASAC Document 272 - MASAC ...
Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic ...
Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approach in hemophilia. Since the 1950s, when prophylaxis started, factor concentrates have been improved with virus inactivation and molecule modification to ...
This paper is a must-read for those who want to learn the story of gene therapy in haemophilia. PubMed Google Scholar Nathwani, A. C. Gene therapy for hemophilia.
1. INTRODUCTION. Hemophilia is an inherited bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or IX (hemophilia B), both X‐linked recessive disorders. 1 Clinical manifestations relate to bleeding, bleeding sequelae, or complications of coagulation factor infusion. 2 It affects more than 1.2 million individuals worldwide, almost exclusively males. 3 Hemophilia ...
About the Journal. Haemophilia is an international haematology journal dedicated to the worldwide exchange of information regarding the comprehensive care of haemophilia and blood disease. We are the official journal of both the World Federation of Hemophilia and the European Association for Haemophilia and Allied Disorders.
emophilia derived from the Greek haima (Blood) and philia (Love), is a genetic bleeding disorder. caused by the def iciency of c lotting factor-VIII. (Hemophilia-A) or factor-IX (Hemophilia-B) or ...
Mainstay haemophilia treatment, namely intravenous factor replacement, poses several clinical challenges including frequent injections due to the short half-life of recombinant factors, intravenous administration (which is particularly challenging in those with difficult venous access), and the risk of inhibitor development. These impact negatively upon quality of life and treatment compliance ...
The purpose of this narrative review was to provide an overview that allows readers to improve their understanding of hemophilia A, which is considered a genetic disease with a high impact on the quality of life of people who suffer from it is considered one of the diseases with the highest cost for health systems (In Colombia it is part of the five diseases with the greatest economic impact ...
In order for a paper to be accepted for publication in a scientific journal, it must address a good research question, report the results of a well-designed study, and be written clearly. A good research question is clinically important, novel and timely—the right question at the right time. There are some helpful websites. The
The purpose of this narrative review of the recent literature is to analyze the outcomes, complications, and implant survival of total knee arthroplasty (TKA) carried out on people with hemophilia (PWH). It has been shown that TKA substantially alleviates preoperative pain and improves knee function and the patient's quality of life. However, the complication rates of TKA range between 8.5% ...
Abstract. Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approach in hemophilia. Since the 1950s, when prophylaxis started, factor concentrates have been ...